Tackling other ‘undruggable’ targets:
The researchers say this novel PLP platform represents a significant advancement in therapeutic development, offering a new tool to tackle challenging biological targets where traditional approaches have fallen short. With Grove Biopharma, researchers are developing PLPs to target protein-protein interactions in various diseases, with an initial focus on cancer and neurodegenerative diseases.
“Proteins are the molecular machines that drive all essential cellular function, and dysregulated intracellular protein-protein interactions are the cause of many human diseases,” Gianneschi said. “Existing drug modalities are either unable to penetrate cells or cannot effectively engage these large disease target domains. We are looking at these challenges through a new lens, and I am excited to continue collaborating with the Grove team to help advance this new modality to the clinic.”
The study was supported by the National Institutes of Health National Heart, Lung, and Blood Institute.
